CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 29734384.
- Also identified by DOI 10.1371/journal.pone.0196931 and PMC identifier 5937768.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Mitotane is the reference drug for adrenocortical carcinoma (ACC) and the metabolic activation of the drug is considered as essential for its activity. The aim of this study was to assess the role of CYP11B1 on mitotane action and metabolism in H295R ACC cells to understand whether this enzyme may influence mitotane action. The simultaneous incubation with mitotane and metyrapone, an adrenolytic molecule targeting 11-beta-hydroxylase, did not influence mitotane-mediated cytotoxic effect and metabolism in H295R ACC cells. CYP11B1 silencing confirmed the lack of a significant metyrapone effect on mitotane action. The present findings do not support the view that CYP11B1 catalyzes a crucial step in the metabolic activation of mitotane and that CYP11B1 confers the adrenal specificity to mitotane.
Medical subject headings
- Adrenocortical Carcinoma
- Cell Proliferation
- Mitotane
- Steroid 11-beta-Hydroxylase